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ABSTRACT 
Background: The Lymphoedema Evaluation in Gynecological cancer Study (LEGS) was a longitudinal, 
observational, cohort study prospectively evaluating the incidence and risk factors of lower-limb lymphedema 
after treatment for gynecological cancer. Here we describe the study protocol and characteristics of the sample.  
Methods: Women with a newly diagnosed gynecological cancer between June 1, 2008 and February 28, 2011, 
aged 18 years or older, and treated at one of six hospitals in Queensland, Australia, were eligible. Lymphedema 
was assessed by circumference measurements, bioimpedance spectroscopy, and self-reported swelling. LEGS 
incorporated a cohort of patients requiring surgery for benign gynecological conditions for comparison purposes. 
Data were collected prior to surgery and at regular intervals thereafter up to 2-years post-diagnosis.  
Results: 546 women participated (408 cancer, 138 benign), with a 24-month retention rate of 78%. Clinical and 
treatment characteristics of participants were similar to the Queensland gynecological cancer population, except 
for a higher proportion of early-stage cervical cancers recruited to LEGS compared with Queensland proportions 
(89% versus 55%, respectively).  
Discussion: Few imbalances were observed between participants with complete and incomplete follow-up data. 
The prospective design and collection of objective and patient-reported outcome data will allow comprehensive 
assessment of incidence and risk factors of lower-limb lymphedema. 
Keywords: cohort; gynecological cancer; longitudinal; lymphedema; observational; prospective. 
 
INTRODUCTION 
The lymphatic vascular system complements the 
venous and arterial vessel systems in the body. It 
drains and transports fluids, proteins and immune-
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competent cells (lymphocytes). Defects in the 
lymphatic system can lead to primary (congenital) 
lymphoedema or secondary (acquired) 
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lymphoedema. It has been estimated that one in 30 
people worldwide develop LE (1), highlighting the 
magnitude of this condition. Primary lymphoedema 
accounts for 10% of all lymphoedema patients (1). 
Secondary lymphoedema (LE) is most recognizably 
associated with parasite infection in developing 
countries, and following treatment for cancer in 
developed countries. Secondary LE after cancer is 
thought to be caused through removal of lymph nodes 
and damage to lymph vessels during treatment 
(surgery, radiotherapy) resulting in reduced flow or 
stasis of lymph fluid.
 
Not eligible (n = 1,385) 
Treatment not scheduled (n = 472) 
Investigator Discretion (n = 351) 
Logistical Reasons (n = 334) 
Unable to comply with follow-up schedule (n = 99) 
Geographical reasons (n = 64) 
Suspected/confirmed non-gynecological cancer (n = 27) 
Recurrence (n = 12) 
Pregnant (n = 10) 
Not capable of consent (n = 6) 
Borderline cases reclassified as ineligible (n = 6) 
Under 18 years of age (n = 4) 
Did not provide consent (n = 190) 
Pre-surgery / Baseline assessment, Time 1 (n = 546)* 
Malignant diagnosis (n = 408) Benign diagnosis (n = 138) 
 
Patients assessed for eligibility 
(n = 2,121) 
6 weeks to 3 months, Time 2 (n = 459) 
Malignant diagnosis (n = 350) Benign diagnosis (n = 109) 
 
6 to 12 months, Time 3 (n = 460) 
Malignant diagnosis (n = 343) Benign diagnosis (n = 117) 
 
15 to 24 months, Time 4 (n = 426) 
Malignant diagnosis (n = 320) Benign diagnosis (n = 106) 
 
Figure 1. Flow Chart of Participant Recruitment and Retention 
* Borderline cases were reviewed and seven (n=7) were reclassified as malignant. 
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Secondary cancer-related LE poses a significant 
burden for cancer survivors. LE is an 
independent predictor of decreased quality of 
life, affecting psychological wellbeing, body 
image, pain, sexual wellbeing, energy, physical 
mobility, financial wellbeing (2-9) and 
potentially survival (10). Given increasing cancer 
incidence and survival rates (11, 12), the 
incidence of secondary LE is also expected to 
increase. For women with breast cancer, a large 
body of evidence, including high quality, 
prospectively designed population-based cohort 
studies, demonstrate that about 20% will develop 
secondary upper-limb LE, with the majority of 
cases presenting within 24 months post-diagnosis 
(13). Strong evidence (i.e., includes at least two 
prospective cohort studies) has been found for 
extensive surgery and being overweight or obese 
as risk factors for breast cancer-related LE (13). 
In contrast, estimates of LE risk following 
gynecological cancer are crude and imprecise. 
While it seems likely that lower-limb LE 
following gynecological cancer is at least as 
common as upper-limb secondary LE following 
breast cancer (14), individual studies report wide 
variation in the incidence of between 1% and 
72% (15-37). Furthermore, there is a paucity of 
literature on risk factors among gynecological 
cancer survivors with only specific aspects of the 
treatment (i.e., extensive surgery, number of 
lymph nodes removed, surgical wound infection) 
thought, but yet to be confirmed, to contribute 
(38). 
Current work investigating lower-limb LE 
following gynecological cancer is restricted by 
self-report LE assessment, retrospective study 
design and/or limited follow-up period 
(maximum follow-up period is six months post-
surgery (39, 40)). Lessons learnt from the breast 
cancer-related LE setting clearly demonstrate 
that to improve understanding of secondary LE, 
longitudinal, cohort studies with prospective and 
comprehensive LE assessment (including self-
report and objective measures) and follow-up of 
at least 24 months post-diagnosis are needed. The 
Lymphedema Evaluation in Gynecological 
cancer Study (LEGS) is unique in Australia and 
indeed worldwide in its aim to establish the 
incidence and prevalence of LE in a prospective 
study of women pre- to 24 months post-surgery 
for gynecological cancer. The purpose of this 
paper is to provide a detailed report of the LEGS 
study protocol, to describe the characteristics of 
the sample and to evaluate sample 
generalizability to the wider gynecological 
cancer cohort. 
 
METHODS 
Study design 
The prospective, longitudinal LEGS cohort study 
was designed to evaluate the prevalence, 
incidence and risk factors of lower-limb LE after 
diagnosis and treatment for gynecological 
cancer. In parallel, a cohort of patients 
undergoing surgery for benign gynecological 
diseases was also recruited to assess the impact 
of surgery for causes other than cancer on lower-
limb LE. In 2009, LEGS received scientific 
support and approval from the Australian and 
New Zealand Gynecological Oncology Group 
(ANZGOG 0901). 
Eligibility criteria 
Women with newly diagnosed gynecological 
cancer (International Classification of Diseases 
Codes C51-C58) between June 1, 2008 and 
February 28, 2011, aged 18 years or older, and 
treated at one of six hospitals in Queensland, 
Australia, were eligible for enrolment. Cancer 
treatment for gynecological cancer in 
Queensland is largely centralized with all 
gynecological oncologists working together 
within the Queensland Centre for Gynecological 
Cancer (QCGC) including both public and 
private hospitals. The QCGC represents virtually 
all gynecological cancer patients in Queensland, 
with some small percentage difference due to 
death certificate-only notifications. Patients were 
considered eligible to participate if they were not 
pregnant, were able to provide informed consent 
and were likely to return to the hospital for 
follow-up care. Patients with a pacemaker, 
allergies against adhesive electrodes or extensive 
internal metal plates were ineligible for 
bioimpedance spectroscopy (BIS) measurement, 
but if they met the eligibility criteria otherwise, 
were still offered to participate in all other 
components of the study. 
Recruitment process 
Following ethical approval from hospital Human 
Research Ethics Committees (approval numbers: 
2008000211, 2007/168, 200842, 1189A/P, 
08/16, 10/14, 10/10/RPAH/28), medical staff at 
the surgical gynecological oncology departments 
recruited patients, which involved undertaking 
initial screening to confirm eligibility, discussion 
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of study, and informed consent. This typically 
occurred when patients were admitted to hospital 
for pre-surgical assessment. Once consent and 
eligibility were established, research staff 
conducted all further procedures. 
Assessment schedule 
A baseline assessment taking approximately 30-
40 minutes per participant was typically 
performed during the consented patient’s pre-
admission clinic, the week prior to surgery. 
Subsequent assessments for cancer patients were 
coordinated with their usual schedule of hospital 
follow-up visits up to two years post-surgery. 
The number of follow-up visits differed for each 
hospital but could be as regular as once every 
three months. Patients with benign diagnoses 
were assessed pre-operatively, at the six-week 
follow-up visit and were called in for at least one 
subsequent assessment. Follow-up study visits 
were held at the treating hospital. 
Data collection 
Standardized data collection protocols were used 
to collect data via clinical assessment, self-
administered questionnaire, and clinical records. 
Research staffs involved with data collection had 
tertiary qualifications in a health-related 
discipline and were trained in the objective 
assessment of lymphedema, including BIS and 
circumference methods, by an accredited 
physiotherapist with specialist skills in 
lymphedema assessment and treatment (HRH). A 
reliability study was conducted to assess the 
intra- and inter-rated consistency for BIS and 
circumference assessments between staff. Inter-
tester reliability was found to be high with 
interclass coefficients of 0.93 (95% confidence 
interval (CI): 0.66, 0.98) to 0.99 (95% CI: 0.96, 
1.00) for circumference and BIS measurements, 
respectively. Bland Altman analysis also 
demonstrated that the mean difference and limits 
of agreement between our highly trained study 
personnel for measures of lymphedema ranged 
between 0.01 (95% CI: -0.08, 0.10) and 0.04 
(95% CI: -0.03, 0.10) for BIS and 0.01 (95% CI: 
-2.91, 2.94) and 0.58 (95% CI: -1.25, 0.90) for 
circumferences. As such, inter- and intra-tester 
agreement of measures of our primary outcome 
were high (<0.5% difference).   
Clinical assessment 
Bioimpedance spectroscopy (BIS) (ImpediMed 
SFB7) electrodes were placed on hands and feet 
at anatomical locations optimized for the 
measurement of limb impedance (41) including: 
middle of styloid process of right and left arm; 
distal end of third metacarpal on the right and left 
hand; lateral malleolus of the fibula on the right 
and left leg; and distant end of the third 
metatarsal on the right and left foot. 
Measurements were taken for each limb, 
according to standard ImpediMed protocol. BIS 
data were analyzed and checked for quality using 
Bioimp v4.15.0 (ImpediMed). 
Circumference measurements followed the 
standard measurement protocol available from 
the Australasian Lymphology Association (42) 
(measuring every 10 centimeters from the heel 
working proximally). The standard method 
involves the use of a measuring board and a set-
square to mark the limb medially and laterally 
every 10 centimeters from the heel. The patient 
lies down with the leg slightly abducted and 
resting on the measuring board with the sole of 
the foot flat against the end of the board and the 
dorsal surface of the foot aligned and facing 
upward. The other leg was supported at the hip 
during measurement to avoid rotation of the 
pelvis during marking of the limb (43). 
Clinical assessments at baseline as well as all 
subsequent data collection sessions also included 
measurement of height and weight using a 
standardized tape measure and a calibrated scale 
and documented in SI units. 
Self-administered questionnaire 
Self-reported swelling. At every data collection 
session, women were asked to answer ‘yes’, ‘no’ 
or ‘unsure’ to the question, ‘Have you 
experienced swelling in both legs?’ with a ‘yes’ 
response being used to indicate the presence of 
self-reported leg swelling. The same question 
was asked for each of the following regions: right 
leg only, left leg only, between legs (vulva), 
lower abdomen, or pelvic region. Anatomical 
sites were condensed into three regions of 
swelling: legs, vulva, and abdomen/pelvis. 
Lower-limb symptoms. Women were asked to 
report on a five-point scale for severity, within 
the last  week, including ‘none’, ‘mild’, 
‘moderate’, ‘severe’ and ‘extreme’ the presence 
of 14 lower-limb symptoms that have been found 
to be associated with upper-limb LE following 
breast cancer (44). The 14 patient self-reported 
lower-limb symptoms included: pain, pain when 
you performed any specific activity, tingling 
(pins and needles), weakness, stiffness, poor 
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range of movement, numbness, tightness, ache, 
heaviness, reddish skin coloring, tenderness, 
thickened/hardened skin, hot areas on your skin. 
Secondary outcomes. Additionally, at baseline as 
well as all subsequent data collection sessions, 
patients completed standardized questionnaires 
on quality of life (Functional Assessment of 
Cancer Therapy-General, FACT-G (45)), body 
image (Body Image Scale (46)), anxiety and 
depression (Hospital Anxiety and Depression 
Scale, HADS (47)), and physical activity (Active 
Australia Survey (48)), as well as questions on 
financial impact of LE. Standardized 
questionnaires pertaining to health services use 
(49), as well as the EuroQol Group (EQ-5D-3L 
(50)) standardized questionnaire, were included 
at the six-week questionnaire and thereafter. 
At the pre-operative (baseline) visit only, 
participants were asked to complete questions on 
demographics and behavioral characteristics 
(e.g., smoking status, alcohol consumption). 
Case Report Forms 
Pre-surgical assessment. Relevant information 
was collected at the patients’ pre-operative visit, 
including menstrual status, medical conditions 
(e.g., past history of cancer, cardiac conditions, 
diabetes and auto-immune diseases), baseline 
medications (i.e., that could have an effect on the 
patient’s fluid balance), and overall quality of life 
(single item). Weight, height, BIS and 
circumference measurements were also taken. 
Follow-up assessments collected information on 
the following; menstrual status, adverse events 
(e.g., seroma, wound infection, lymphedema), 
concomitant medications, and overall quality of 
life. Leg measurements (BIS and 
circumferences) were also taken, and women 
were asked if they had received any treatment for 
LE since their last visit and, if so, by whom. 
Treatment data abstracted from participant’s 
clinical file at the two year final follow-up visit 
included type of surgery performed, number of 
lymph nodes dissected and number positive, 
histopathology, adjuvant treatments and patient 
status (living tumor free, living with the tumor, 
progressive disease, and death). 
Clinical diagnosis and referral to services. As 
the study itself did not provide treatment to 
patients who developed LE, women were 
referred back to their General Practitioner for 
further assessment and treatment if any of the 
following were recorded: >5% increase in leg 
circumference measurements when compared 
with pre-surgical measurements in two 
consecutive visits; or >5% increase in leg 
circumference measurements when compared 
with pre-surgical measurements plus significant 
patient-reported leg symptoms. Participants were 
also advised to visit their General Practitioner if 
they were concerned or noticed swelling between 
study visits. 
Sample size calculations and power 
A priori sample size calculations were based on 
the primary outcome, incidence of lower-limb 
LE. Assuming an incidence of at least 20% of 
patients with LE within the malignant group (82 
out of 408 patients), power is 100% to be able to 
detect as statistically significant with 95% 
confidence intervals around estimates of LE 
incidence in the range of +7%. Higher incidence 
rates of LE generally will increase statistical 
power (i.e., provide narrower confidence 
intervals). 
Data management 
Participants were assigned a unique anonymous 
number which was used to track their progress 
through the study and to match their Case Report 
Forms, written forms and electronic files. Data 
from Case Report Forms and questionnaires were 
entered into a password protected database. A 
comprehensive validation check program was 
used to verify the data (e.g., identifying values 
outside the possible range) and discrepancy 
reports were generated accordingly for resolution 
by the investigator. Data were stored in locked 
offices or password-protected computer files, 
accessible only by study staff. Data verification 
on a 10% random sample of participant 
questionnaires was performed and compared 
with original data entry files. The error rate 
between the files was <2% and the original 
therefore retained. 
Statistical analysis 
Information from up to 10 data collection points 
was available, however follow-up schedules 
across the six hospitals varied as did assessments 
for malignant and benign diagnoses, and were 
thus grouped into four phases: Time 1 = baseline; 
Time 2 = 6 weeks to 3 months; Time 3 = 6 to 12 
months; Time 4 = 15 to 24 months post-surgery.  
Of particular interest for this manuscript were 
recruitment and retention rates, characteristics of  
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   Table 2. Demographic, Clinical and Treatment Characteristics of LEGS Participants by Diagnosis 
Characteristic Benign 
N (%) 
Endometrial 
N (%) 
Ovarian 
N (%) 
Cervical 
N (%) 
Vulvar/ 
Vaginal 
N (%) 
Number of cases 138 235 114 37 22 
Age at diagnosis, years 
 Mean (SD) 
 
51 (11.9) 
 
62 (10.1) 
 
60 (11.1) 
 
48 (12.0) 
 
57 (12.3) 
Histological type 
 Adenocarcinoma 
 Squamous cell 
 Adenosquamous 
 Serous carcinoma 
 High-risk epithelial 
 Mesenchymal 
 Epithelial, high grade serous 
 Epithelial, other 
 Non-epithelial 
 Endometroid carcinoma 
 Other 
 Benign 
 Benign with prior diagnosis 
 Borderline 
 
- 
- 
- 
 
 
 
 
 
 
 
- 
124 (89.9) 
4 (2.9) 
10 (7.2) 
 
176 (74.9) 
1 (0.4) 
1 (0.4) 
4 (1.7) 
14 (6.0) 
14 (6.0) 
- 
- 
- 
3 (1.3) 
4 (1.7) 
- 
18 (7.7) 
- 
 
36 (31.6) 
- 
- 
38 (33.3) 
- 
- 
12 (10.5) 
8 (7.0) 
7 (6.1) 
- 
4 (3.5) 
- 
4 (3.5) 
5 (4.4) 
 
4 (10.8) 
14 (37.8) 
- 
- 
- 
- 
- 
- 
- 
- 
2 (5.4) 
- 
17 (45.9) 
- 
 
- 
14 (63.6) 
- 
- 
- 
- 
- 
- 
- 
- 
2 (9.1) 
1 (4.5) 
5 (22.7) 
- 
Surgery 
 Midline incision 
 Lower transverse 
 Laparoscopy 
 Vulval/Vaginal-related 
 Surgery abandoned 
 Other 
 Missing 
 
39 (28.3) 
3 (2.2) 
83 (60.1) 
9 (6.5) 
1 (0.7) 
3 (2.2) 
0 (0.0) 
 
89 (37.9) 
18 (7.7) 
123 (52.3) 
0 (0.0) 
1 (0.4) 
1 (0.4) 
3 (1.3) 
 
101 (88.6) 
1 (0.9) 
6 (5.3) 
0 (0.0) 
2 (1.8) 
2 (1.8) 
2 (1.8) 
 
4 (10.8) 
9 (24.3) 
22 (59.5) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
2 (5.4) 
 
1 (4.5) 
0 (0.0) 
1 (4.5) 
14 (63.6) 
0 (0.0) 
6 (27.3) 
0 (0.0) 
Lymph node dissection 
 No 
 Yes 
 
138 (100) 
- 
 
128 (54.5) 
107 (45.5) 
 
71 (62.3) 
43 (37.7) 
 
11 (29.7) 
26 (70.3) 
 
17 (77.3) 
5 (22.7) 
Number of nodes removed 
 Median (min, max) 
 Mean (SD) 
 
- 
 
6.0 (0, 36) 
7.6 (8.0) 
 
5.5 (0, 32) 
7.6 (7.8) 
 
12.5 (0,31) 
14.0 (7.9) 
 
4 (0, 21) 
6.7 (6.5) 
Number of nodes metastatic 
 Median (min, max) 
 Mean (SD) 
 
- 
 
0 (0, 10) 
0.3 (1.1) 
 
0 (0, 9) 
0.6 (1.6) 
 
0 (0, 2) 
0.4 (0.7) 
 
0 (0, 3) 
0.4 (0.8) 
Relapse during study period 
 No know relapse 
 Yes 
 
131 (94.9) 
7 (5.1) 
 
200 (85.1) 
35 (14.9) 
 
74 (64.9) 
40 (35.1) 
 
33 (89.2) 
4 (10.8) 
 
16 (72.7) 
6 (27.3) 
Relapse site* 
 Pelvic 
 Vault 
 Abdominal 
 Vulval/Vaginal 
 Distant 
 New primary# 
 Unknown 
 
1 (14.4) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
3 (42.8) 
3 (42.8) 
 
11 (31.4) 
6 (17.1) 
5 (14.3) 
0 (0.0) 
5 (14.3) 
8 (22.9) 
0 (0.0) 
 
17 (42.5) 
0 (0.0) 
13 (32.5) 
0 (0.0) 
10 (25.0) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
1 (25.0) 
0 (0.0) 
0 (0.0) 
1 (25.0) 
2 (50.0) 
0 (0.0) 
 
2 (33.3) 
0 (0.0) 
0 (0.0) 
3 (50.0) 
0 (0.0) 
1 (16.7) 
0 (0.0) 
Status 
 Alive 
 Deceased 
 
138 (100) 
0 (0.0) 
 
219 (93.2) 
16 (6.8) 
 
97 (85.1) 
17 (14.9) 
 
35 (94.6) 
2 (5.4) 
 
20 (90.9) 
2 (9.1) 
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Characteristic Benign 
N (%) 
Endometrial 
N (%) 
Ovarian 
N (%) 
Cervical 
N (%) 
Vulvar/ 
Vaginal 
N (%) 
 
Cause of death 
 Gynecological cancer 
 Unrelated morbidity 
 Unknown 
 
- 
- 
- 
 
12 (74.8) 
1 (6.3) 
3 (18.8) 
 
15 (88.2) 
1 (5.9) 
1 (5.9) 
 
2 (100) 
- 
- 
 
2 (100) 
- 
- 
* One endometrial patient had two relapse sites (pelvic and abdominal recurrence) and has been counted in both groups.  
# New primary sites: breast (n=4), lung (n=2), colon (n=2), skin melanoma (n=2), face skin (n=2), ovarian with prior 
endometrial (n=1), pituitary (n=1). 
 
 
our sample and sample generalizability. 
Recruitment rates were calculated by the number 
of consenting and participating women divided 
by the number of eligible women approached to 
participate. Retention rates equaled the number 
of participants who completed follow-up testing 
divided by the number of participants who 
completed baseline testing. Baseline participant 
characteristics were described using mean and 
standard deviation (SD) for normally-distributed, 
continuous characteristics; median, minimum 
and maximum for non-parametric data; and 
proportions for categorical characteristics. The 
clinical and treatment characteristics of LEGS 
participants were compared with the population 
of women treated for gynecological cancer in 
Queensland in 2009. The comparison data were 
made available from the QCGC; this is the largest 
gynecological cancer service in Australia and 
houses a population-based registry of 
Queensland gynecological cancer patients. A 
priori absolute differences between groups of 
>10% were considered relevant. Characteristics 
for participants with complete (i.e., four phases) 
and incomplete (i.e., fewer than four phases) 
follow-up data were also compared using Chi-
squared tests to explore the sampling 
distributions. Statistical significance of P<0.05 
(Fisher’s Exact Test used where available, 
otherwise Pearson Chi-Squared used) for all 
personal, treatment and disease characteristics 
between participants with complete versus 
incomplete follow-up data were considered 
relevant. When there was an overall statistically 
significant difference between groups, post-hoc 
analyses using standardized residuals (converted 
to a z-score, +1.96) were performed to 
investigate which category differed between the 
groups. 
 
RESULTS 
Recruitment and retention 
Of the 2,121 potentially eligible participants, 
65% (n=1,385) were excluded due to not meeting 
the inclusion criteria and 9% (n=190) declined to 
participate (see Figure 1). Of the 546 women who 
remained eligible and gave informed consent, 
408 were diagnosed with malignant disease and 
138 with benign disease. All women had baseline 
measurements taken pre-surgery (i.e., prior to 
their first surgery). The study retention rates at 
Times 2, 3 and 4 were 84% (86% malignant; 80% 
benign), 84% (84% malignant, 85% benign), and 
78% (78% malignant; 77% benign), respectively. 
Examples of benign conditions among 
participants included: benign ovarian cysts or 
tumors, endometrial hyperplasia with or without 
atypia, adenomyosis, uterine fibroids as well as 
vulval intraepithelial neoplasia (VIN) III. 
Generalizability 
On the whole, characteristics of the participants 
of LEGS and the wider gynecological cancer 
population were comparable (Table 1). A higher 
proportion of stage I cervical cancer cases were 
involved in the LEGS study compared with 
Queensland proportions (89.2% versus 55.0%, 
respectively); likely because only those women 
with early-stage cervical cancer are referred to 
the surgical gynecological oncology department, 
which is where participants were recruited from. 
Subsequently, a greater proportion of LEGS 
cervical cancer participants underwent surgery 
(95% versus 52%, respectively), and fewer 
received chemotherapy (24% versus 48%, 
respectively), external beam radiotherapy (27% 
versus 52%, respectively), or brachytherapy (8% 
versus 30%, respectively) compared with the 
Queensland population of cervical cancer 
patients. 
Table 2. Continued 
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Baseline characteristics 
Women who were deemed eligible following 
baseline assessment and who participated in at 
least one follow-up data collection session will 
contribute to further analyses, including 138 
women with benign disease, 235 endometrial, 
114 ovarian, 37 cervical, 22 vulvar/vaginal 
cancer cases (see Table 2). 
Participants with complete follow-up data 
versus incomplete follow-up data 
Participants with complete follow-up data (i.e., 
data available for all four phases) were compared 
with participants with incomplete follow-up data 
(i.e., data available for less than four phases) for 
malignant (n = 249 versus 159, respectively) and 
benign (n = 84 versus 54, respectively) disease 
separately (see Table 3). 
Malignant disease. Many demographic, general 
health, clinical and treatment characteristics were 
similar for the women in this study with and 
without complete follow-up data, including age, 
menstrual status, histological type, surgery, 
lymph node dissection, radiotherapy and relapse 
status. Women with incomplete follow-up data 
had more missing demographic (education, child 
status, health insurance, household income) and 
general health (smoking status) data. The group 
of participants with incomplete follow-data were 
more likely to be past drinkers (16% versus 6%, 
respectively), diagnosed with stage III disease 
(28% versus 16%, respectively) and to have 
received chemotherapy (48% versus 36%, 
respectively) compared with the group of 
participants with complete follow-up data. They 
were also less likely to be married or in a de facto 
relationship (42% versus 65%, respectively), 
born in Australia (52% versus 74%, 
respectively), classified as obese (23% versus 
34%, respectively), diagnosed with endometrial 
cancer (47% versus 65%, respectively), and to be 
alive at the end of the study period (82% versus 
96%, respectively) compared with those with 
complete follow-up data. 
Benign disease. Demographic, general health, 
clinical and treatment characteristics were 
similar for the women in this study with and 
without complete follow-up data. Those with 
incomplete follow-up data were missing more 
demographic (child status, health insurance, 
household income, country of birth) and general 
health (drinking status) information than those 
with complete follow-up data. Those with 
incomplete follow-up data were more likely to 
have undergone midline incisional surgery (35% 
versus 24%, respectively) and less likely to have 
a laparoscopy (46% versus 69%, respectively) 
compared with those with complete follow-up 
data. No further differences were noted. 
 
DISCUSSION 
Findings presented here clearly demonstrate the 
successful recruitment of women into LEGS with 
a sample size adequate to statistically meet the 
primary objectives of the study. Retention rate 
for LEGS was high, with the majority of 
participants followed for up to two years 
following surgery (the maximum in the literature 
is to six months (39, 40)). The length of follow-
up will allow us to capture delayed development 
of the lymphedema, as has been documented in 
the breast cancer setting. Further, the LEGS 
sample is generally representative of the wider 
Queensland gynecological cancer population and 
therefore upcoming results are likely to be 
generalizable to this broader group. 
The LEGS study is able to provide prospective 
evaluation of the onset, incidence and risk factors 
of lower-limb lymphedema after treatment for 
gynecological cancer up to two years following 
diagnosis of gynecological cancer. Similar 
studies are currently underway in the United 
States (ClinicalTrials.gov Identifiers: 
NCT00956670, NCT01406769). Like LEGS, 
they are recruiting women undergoing surgery 
for gynecological cancer and prospectively 
investigating the incidence of lower-limb LE via 
multiple methods up to 24 months post-
operatively. Unlike LEGS, exclusion criteria are 
placed on stage of disease (endometrial stage I-
II; cervical stage I-IIA), ovarian cancer is not 
included, and BIS measurements are only taken 
on women diagnosed with vulvar cancer. Despite 
these differences there will be sufficient 
comparable data to allow estimation of 
similarities and differences in risk factors for LE. 
A notable strength of LEGS is the thorough 
assessment of LE, including objective and self-
report assessment. The objective methods of 
assessment include the measure typically used in 
clinical practice (i.e., circumferences), as well as 
the most sensitive method of assessment capable 
of diagnosing the condition before it presents 
clinically (BIS). In addition, lymphedema 
detected during routine clinical follow-up and 
participant self-report of swelling and associated 
symptoms has been assessed. This 
comprehensive assessment of the primary 
outcome will allow for a detailed investigation on 
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how best to measure and define LE in its early 
stages and throughout its progression, with the 
time-course of transitioning from stage 0 through 
to stage IV lymphedema currently unknown. 
This is exactly the type of information necessary 
to identify the pros and cons of the various 
lymphedema diagnostic methods. We will use 
this information to guide future clinical practice 
with respect to the most optimal lymphedema 
diagnostic tool. 
LEGS also involved measurement of a wide 
range of personal, diagnostic, treatment and 
behavioral characteristics, which in turn will 
enable us to properly explore potential LE risk 
factors, and to describe the relationship between 
LE, quality of life, financial burden and survival. 
Further, by recruiting benign cases in parallel 
with women with malignant disease, we will be 
able to distinguish between LE developed as a 
consequence of surgery alone versus surgery plus 
additional treatment. LEGS took place within the 
QCGC, the largest clinical and treatment unit of 
its kind in the Southern Hemisphere. As such, 
there is great potential for its findings to identify 
risk reduction strategies and inform lymphedema 
prevention guidelines and survivorship care 
practices. 
A few shortcomings of LEGS should be noted. 
Statistical power may be low among cancer 
subgroups, limiting our ability, for example, to 
identify cancer-specific risk factors. Due to 
recruitment through the surgical gynecological 
oncology department lower participation rates 
among women with higher stage cervical cancer 
assigned to chemo-radiation treatment may 
underestimate the true rates of LE present in the 
gynecological cancer population, or overestimate 
it if surgery is the main driver. Nonetheless, the 
recruitment and retention rates of the 
generalizable sample of LEGS make it clear that 
we will confirm LE prevalence and incidence 
following gynecological cancer, and identify risk 
factors for its development (including 
measurement of risk factors not previously 
assessed in the upper-limb setting), as well as 
potential prevention and treatment strategies. The 
proposed alternative models for diagnosing LE 
will allow us to compare their reliability and 
sensitivity, which in turn will be valuable for 
future clinical care, as using the most sensitive 
measure will promote early diagnosis and referral 
to treatment. Finally, the comprehensive 
assessment of the primary outcome, LE, 
alongside the assessment of other important 
physical and psychosocial outcomes, has set the 
scene for advancing our understanding of 
gynecological cancer survivorship in a way that 
will be able to influence the lives of women 
diagnosed with gynecological cancer, as well as 
public health burden from the disease. 
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Table 3. Baseline Characteristics of LEGS Participants with Complete Follow-up Data (4 phases) 
Compared With Incomplete Follow-up Data (<4 phases) 
Characteristic Malignant Benign 
Complete 
N (%) 
Incomplete 
N (%) 
Complete 
N (%) 
Incomplete 
N (%) 
Total patients 249 159 84 54 
Demographic characteristics 
Age at diagnosis, years 
 Mean (SD) 
 Median (minimum, maximum) 
 
60.5 (10.3) 
60 (34, 85) 
 
59.0 (12.9) 
60 (27, 90) 
 
53.5 (11.9) 
51 (28, 82) 
 
50.2 (11.7) 
51 (22, 75) 
Highest education 
 Grade 12 or below 
 Trade/University 
 Other 
 Missing 
 
153 (61.5) 
73 (29.3) 
9 (5.7) 
7 (2.8)# 
 
74 (46.5) 
41 (25.7) 
9 (5.7) 
35 (22.1) # 
 
54 (64.3) 
25 (29.8) 
3 (3.6) 
2 (2.3) 
 
23 (42.7) 
22 (40.7) 
3 (5.6) 
6 (11.0) 
Employment status 
 Full-time/Part-time/casual 
 Home duties 
 Other 
 Missing 
 
59 (23.7) 
66 (26.5) 
116 (46.5) 
8 (3.3) 
 
35 (22.0) 
31 (9.5) 
59 (37.1) 
34 (21.4)+ 
 
28 (33.3) 
34 (40.5) 
21 (25.0) 
1 (1.2) 
 
19 (35.2) 
13 (24.1) 
16 (29.8) 
6 (10.9)+ 
Marital status 
 Married/de facto 
 Not married 
 Missing 
 
161 (64.7) 
77 (32.6) 
7 (2.7) 
 
67 (42.1) 
58 (36.5) 
34 (21.4)+ 
 
59 (70.2) 
24 (28.5) 
1 (1.3) 
 
30 (55.6) 
18 (33.4) 
6 (11.0) 
Children in care 
 None/never 
 Age 0-14 years 
 Age >14 years 
 Missing 
 
185 (74.3) 
19 (7.6) 
37 (14.9) 
8 (3.2)# 
 
92 (57.9) 
11 (6.9) 
17 (10.7) 
39 (24.5)# 
 
50 (59.5) 
17 (20.3) 
17 (20.2) 
0 (0.0)# 
 
21 (38.9) 
14 (25.9) 
12 (22.2) 
7 (13.0)# 
Health insurance 
 No 
 Yes 
 Missing 
 
164 (65.9) 
81 (32.5) 
4 (1.6)# 
 
86 (54.1) 
39 (24.5) 
34 (21.4)# 
 
40 (47.6) 
43 (51.2) 
1 (1.2)# 
 
24 (44.4) 
23 (42.6) 
7 (13.0)# 
Household income 
 <$20,000 
 $20,000 to $60,000 
 $60,000+ 
 Missing 
 
73 (29.3) 
98 (39.4) 
52 (20.8) 
26 (10.5) # 
 
43 (27.1) 
38 (23.9) 
30 (18.8) 
48 (30.2) # 
 
17 (20.3) 
29 (34.6) 
34 (40.5) 
4 (4.6) # 
 
11 (20.4) 
10 (18.6) 
20 (37.0) 
13 (24.0) # 
Birth country 
 Australia 
 Other 
 Missing 
 
185 (74.3) 
61 (24.5) 
3 (1.2)- 
* 
82 (51.6)- 
44 (27.7) 
33 (20.8)+ 
 
68 (81.0) 
16 (19.0) 
0 (0.0)# 
 
34 (63.0) 
14 (25.9) 
6 (11.1)# 
General health characteristics 
Menstrual status 
 Pre-menopausal 
 Peri-menopausal 
 Post-menopausal 
 
29 (11.6) 
18 (7.2) 
202 (81.1) 
 
26 (16.4) 
9 (5.7) 
124 (78.0) 
 
16 (19.0) 
19 (22.6) 
49 (58.3) 
 
18 (33.3) 
11 (20.4) 
25 (46.3) 
Smoking status 
 Never 
 Past smoker 
 Current smoker 
 Missing 
 
153 (61.4) 
73 (29.3) 
19 (7.6) 
4 (1.6)# 
 
63 (39.6) 
49 (30.8) 
13 (8.2) 
34 (21.4)# 
 
43 (51.2) 
29 (34.5) 
9 (10.7) 
3 (3.6) 
 
23 (42.6) 
17 (31.5) 
8 (14.8) 
6 (11.1) 
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Characteristic Malignant Benign 
Complete 
N (%) 
Incomplete 
N (%) 
Complete 
N (%) 
Incomplete 
N (%) 
Drinking status 
 Never 
 Past 
 Rarely 
 Current 
 Missing 
 
60 (24.1) 
14 (5.6)- 
74 (29.7) 
98 (39.4) 
3 (1.2)- 
* 
21 (13.2) 
26 (16.4)+ 
35 (22.0) 
42 (26.4) 
35 (22.0)+ 
 
10 (11.9) 
10 (11.9) 
21 (25.0) 
41 (48.8) 
2 (2.4)# 
 
7 (13.0) 
5 (9.3) 
17 (31.5) 
17 (31.5) 
8 (14.8)# 
Body mass index 
 Under/normal weight 
 Overweight 
 Obese 
 Missing 
 
122 (49.0) 
41 (16.5) 
86 (34.5) 
0 (0.0) 
* 
88 (55.3) 
33 (20.8) 
36 (22.6) 
2 (1.3) 
 
51 (60.7) 
12 (14.3) 
20 (23.8) 
1 (1.2) 
 
33 (61.1) 
12 (22.2) 
9 (16.7) 
0 (0.0) 
Clinical and treatment characteristics 
Tumour finding 
 Endometrial 
 Ovarian 
 Cervical 
 Vulvar/Vaginal 
 
161 (64.7) 
60 (24.1) 
16 (6.4) 
12 (4.8) 
* 
75 (47.2) 
53 (33.3) 
21 (13.2) 
10 (6.3) 
- - 
Histological type 
 Adenocarcinoma 
 Squamous cell 
 Adenosquamous 
 Serous carcinoma 
 High-risk epithelial 
 Mesenchymal 
 Epithelial, high grade serous 
 Epithelial, other 
 Non-epithelial 
 Endometroid carcinoma 
 Other 
 Benign 
 Benign with prior diagnosis 
 Borderline 
 
142 (57.0) 
13 (5.2) 
1 (0.4) 
21 (8.4) 
10 (4.0) 
8 (3.2) 
8 (3.2) 
5 (2.0) 
6 (2.4) 
2 (0.8) 
6 (2.4) 
1 (0.4) 
22 (8.8) 
4 (1.6) 
 
74 (46.5) 
16 (10.1) 
0 (0.0) 
21 (13.2) 
4 (2.5) 
6 (3.8) 
4 (2.5) 
3 (1.9) 
1 (0.6) 
1 (0.6) 
6 (3.8) 
0 (0.0) 
22 (13.8) 
1 (0.6) 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
76 (90.5) 
3 (3.6) 
5 (6.0) 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
48 (88.9) 
1 (1.9) 
5 (9.3) 
Stage 
 I 
 II 
 III 
 IV 
 Missing 
 
162 (65.1) 
26 (10.4) 
40 (16.1) 
13 (5.2) 
8 (3.2) 
* 
79 (49.7) 
15 (9.4) 
44 (27.7)+ 
14 (8.8) 
7 (4.4) 
- - 
Surgery 
 Midline incision 
 Lower transverse 
 Laparoscopy 
 Vulvar/Vaginal-related 
 Surgery abandoned 
 Other 
 Missing 
 
115 (46.2) 
15 (6.0) 
100 (40.2) 
9 (3.6) 
1 (0.4) 
4 (1.6) 
5 (2.0) 
 
80 (50.3) 
13 (8.2) 
52 (32.7) 
5 (3.1) 
2 (1.3) 
5 (3.1) 
2 (1.3) 
 
20 (23.8) 
1 (1.2) 
58 (69.0) 
5 (6.0) 
0 (0.0) 
0 (0.0) 
- 
* 
19 (35.2) 
2 (3.7) 
25 (46.3) 
4 (7.4) 
1 (1.9) 
3 (5.6) 
- 
Lymph node dissection 
 No 
 Yes 
 
133 (53.4) 
116 (46.6) 
 
94 (59.1) 
65 (40.9) 
 
84 (100) 
- 
 
54 (100) 
- 
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Characteristic Malignant Benign 
Complete 
N (%) 
Incomplete 
N (%) 
Complete 
N (%) 
Incomplete 
N (%) 
Chemotherapy 
 No 
 Yes 
 Missing 
 
157 (63.1) 
90 (36.1) 
2 (0.8) 
* 
77 (48.4) 
77 (48.4) 
5 (3.1) 
- - 
Radiotherapy (EBRT) to whole 
pelvis 
 No 
 Yes 
 Missing 
 
 
7 (2.8) 
50 (20.1) 
192 (77.1) 
 
 
2 (1.3) 
34 (21.4) 
123 (77.4) 
- - 
Intracavity brachytherapy 
 No 
 Yes – HDR 
 Yes – LDR 
 Yes – PDR 
 Missing 
 
35 (14.1) 
17 (6.8) 
2 (0.8) 
0 (0.0) 
195 (78.3) 
 
22 (13.8) 
10 (6.3) 
1 (0.6) 
1 (0.6) 
125 (78.6) 
- - 
Relapse during study period 
 No know relapse 
 Yes 
 
205 (82.3) 
44 (17.7) 
 
118 (74.2) 
41 (25.8) 
 
80 (95.2) 
4 (4.8) 
 
51 (94.4) 
3 (5.6) 
Status 
 Alive 
 Deceased 
 
240 (96.4) 
9 (3.6) 
* 
131 (82.4) 
28 (17.6) 
 
84 (100) 
0 (0.0) 
 
54 (100) 
0 (0.0) 
* P<0.05 between follow-up and baseline-only groups (Fisher’s Exact Test used where available else Pearson Chi-Square 
used). 
# Chi-Square no longer statistically significant when the missing category is removed from the analysis. 
- Standardized residual (converted to a z-score) greater than -1.96 (indicating the cell was under-represented in the actual 
sample compared to the expected frequency); values indicate a difference larger than expected by chance for a p-value of 
0.05. 
+ Standardized residual (converted to a z-score) greater than +1.96 (indicating the cell was over-represented in the actual 
sample compared to the expected frequency); values indicate a difference larger than expected by chance for a p-value of 
0.05. 
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